The stamp is still missing
October–November 2026 trial analyses, regulatory decisions and conference reports
Strong results—so why isn’t the story finished?
Subject One places his folder on the Council’s desk and waits for a celebratory stamp. Doctide adds another dated page instead. “Results are in. The work is not finished.” His shoulders drop, then he opens the folder. There is finally enough history to understand the next question.
What changes here
The evidence has grown, but retatrutide remains investigational. Trial results and regulatory approval are different milestones. [3]
Read the study details & dates
TRIUMPH-1: obesity without diabetes
The published 80-week Phase 3 trial enrolled 2,339 adults. The highest studied arm had a mean 25.0% weight reduction versus 3.9% with placebo using the treatment-regimen, intention-to-treat analysis. Knee-pain and sleep-apnea subgroups were also evaluated; gastrointestinal events were most common. [1]
TRIUMPH-2: obesity and type 2 diabetes
In this Lilly-funded, double-blind Phase 3 trial, 1,152 adults with overweight or obesity and type 2 diabetes received weekly subcutaneous retatrutide or placebo for 80 weeks. The primary-publication abstract reports treatment-regimen weight changes of −11.9%, −16.8% and −18.8% across the three ascending-dose arms versus −5.1% with placebo, using all randomized participants and multiple imputation for missing data. These differ from the sponsor’s efficacy-estimand figures previously summarized here. Gastrointestinal events, hypotension and dysesthesia were more frequent with retatrutide. Discontinuation for adverse events or death was 4%, 12% and 8% versus 5% with placebo. [6] [2]
Unverified products: a new safety-signal study
A cross-sectional Reddit analysis used language-model extraction to identify 13,589 self-reported users; 7,823 remained in the symptom denominator after mapping and exclusions. Fatigue, nausea, insomnia and increased heart rate were reported. These are selected online reports, not verified clinical events or incidence estimates. Product identity, route, dose and medical history could not be confirmed. Earlier semaglutide/tirzepatide datasets provided unmatched descriptive context, not a statistical comparison. [4]
No invented approval ending
Retatrutide remains investigational. FDA states that it is not an approved drug ingredient and cannot be used in compounding under federal law. Research milestones do not authorize retail treatment. [3]
Counterfeit pens: a separate product-quality warning
MHRA reported a Birmingham seizure of over 12,000 counterfeit retatrutide and tirzepatide pens. Their contents and quality were uncertain. This enforcement notice is not a clinical trial, a new approval, or evidence about authentic trial supplies or licensed products; it reports no patient outcomes. [5]
Kidney research in mice—not a demonstrated benefit in adolescents
An eight-week experiment in five-week-old male B6.BKS(D) Leprdb/J mice compared subcutaneous semaglutide and retatrutide with vehicle. Body weight was 18.2% and 14.4% lower than controls, respectively; both groups showed improved glucose handling and less glomerular basement-membrane thickening. The abstract described only marginal filtration-rate improvement with semaglutide. It does not establish superiority between medicines, prevention of kidney failure, or safety and effectiveness in human adolescents. Sample sizes, uncertainty estimates and adverse-event counts were not provided in the accessible abstract. This is preliminary animal evidence, not a peer-reviewed full report or clinical approval. [7]
A kidney biomarker signal, not proof of kidney protection
Lilly researchers analyzed stored serum from subsets of two randomized phase 2 trials: NCT04867785 in adults with type 2 diabetes (281 randomized; 36 weeks; retatrutide, dulaglutide or placebo) and NCT04881760 in adults with obesity without diabetes (338 randomized; 48 weeks; retatrutide or placebo). Participants did not have kidney disease. A post hoc proteomic analysis using mixed models for repeated measures and false-discovery-rate correction found dose-related increases in uromodulin. Associations persisted after adjustment for weight and HbA1c. These are exploratory biomarker associations, not demonstrated prevention of kidney failure or results from a chronic-kidney-disease treatment trial. The abstract does not specify the analyzed subset sizes or provide a new safety analysis; its reported week-48 estimate and confidence interval need clarification before numerical reuse. [8]
Drug or biologic? A classification decision, not an efficacy rejection
Following a court remand, FDA again determined that retatrutide is neither a protein nor an analogous biological product under its regulatory definition. The agency applies a threshold of more than 40 qualifying alpha amino acids and describes retatrutide’s peptide chain as 39. Its public redacted letter directs an application through section 505 of the Federal Food, Drug, and Cosmetic Act, the drug pathway. This decision concerns which regulatory pathway applies; it is not a rejection of a marketing application for inadequate safety or effectiveness, and it does not grant approval. The letter records the earlier March 18, 2024 classification and October 3, 2025 court remand. [9]
Lilly continues its challenge and states a filing plan
In its supplemental brief to the Seventh Circuit in appeal 26-1301, Lilly argued that the court could hear its classification appeal and that FDA’s renewed decision made resolution necessary. Lilly stated that it planned to submit a retatrutide application no later than the first quarter of 2027 and sought clarity on the drug-versus-biologics pathway. This is the company’s litigation position and stated plan—not a judicial ruling, evidence that an application has been submitted, or an approval timetable. The filings reviewed here do not establish a later appellate outcome. [10]
TRANSCEND-T2D-2: a direct comparison with injectable Ozempic
Lilly reported topline results from a randomized, open-label phase 3 trial (NCT06260722): 1,298 adults with type 2 diabetes inadequately controlled on metformin, with or without an SGLT2 inhibitor. Subcutaneous retatrutide 9/12 mg was compared with injectable semaglutide (Ozempic) 2 mg. At 80 weeks, A1C fell 2.2 percentage points in both retatrutide arms versus 1.8; mean weight loss was 19.5%/20.9% versus 9.4%. These efficacy-estimand estimates assume continued assigned treatment, allowing interruptions/modifications, without additional antihyperglycemic medication for over 14 days; they are not treatment-regimen estimates. Adverse-event discontinuations were 4.8%/7.9% versus 2.7%. Gastrointestinal events were common. The release supplies no detailed serious-event/death table or associated causality assessment; absence of those details does not establish absence of harm. These are sponsor-reported findings awaiting a full peer-reviewed report, not approval, a Wegovy comparison, or evidence of superiority to tirzepatide. Retatrutide remains investigational. Trial-arm amounts identify the comparison, not treatment instructions. [11]
TRIUMPH-1 knee-pain results: a distinct analysis
This congress abstract reports the 574-person knee-osteoarthritis basket of TRIUMPH-1 (NCT05929066), not a new independent trial. Adults had painful knee osteoarthritis and BMI ≥27. The 80-week randomized, double-blind study compared weekly subcutaneous retatrutide 4/9/12 mg with placebo. Using an efficacy estimand and mixed models for repeated measures, mean WOMAC pain changes were −3.66/−4.19/−4.30 versus −2.24 points (0–10 scale; each p<0.001). These estimates must not be substituted for the main publication’s intention-to-treat or hybrid estimates. Common adverse events were mild-to-moderate gastrointestinal events. Numerical serious-event/death counts and causality assessments were unavailable in the retrieved abstract text; its safety table was not reviewed. This does not establish absence of serious harm. Authors include Lilly employees. Retatrutide remains investigational; this abstract adds analysis detail, not approval. Trial-arm amounts identify the study, not treatment instructions. [12]
What this does not establish
The next entries will follow verified publications, meaningful safety findings and regulatory decisions. No new result means no invented progress for Subject One.
Original sources
- TRIUMPH-1 primary publication, September 2026
- Lilly TRIUMPH-2 report, September 29, 2026 (sponsor)
- FDA concerns with unapproved GLP-1 drugs
- Sehgal et al., JAMA Network Open research letter, October 14, 2026; doi:10.1001/jamanetworkopen.2026.38929
- MHRA counterfeit-pen enforcement notice, October 15, 2026 (UK regulator)
- Bellido et al., TRIUMPH-2, Lancet 2026; primary-publication abstract reviewed; doi:10.1016/S0140-6736(26)01861-1
- Didik et al., ASN Kidney Week 2026, TH-PO0812 (conference abstract; animal study)
- Park et al., ASN Kidney Week 2026, FR-PO0500 (Lilly-funded conference abstract)
- FDA retatrutide remand decision, October 2, 2026; public redacted original filed October 8 as Seventh Circuit 26-1301, document 46-2
- Eli Lilly supplemental appellate brief, October 8, 2026; Seventh Circuit 26-1301, document 47 (company litigation filing)
- Lilly, TRANSCEND-T2D-2 topline release, October 28, 2026 (sponsor; PRNewswire)
- Hunter et al., ACR Convergence 2026 abstract 2573 (conference abstract; Lilly authors)
Historical sources reviewed October 11, 2026; social-media research letter reviewed October 15. On October 16, the TRIUMPH-2 primary-publication abstract and October 15 MHRA notice were reviewed. The trial was published online September 29, not newly conducted or published today. This is a targeted update, not a fresh review of every earlier study. October 23: targeted review of the newly linked primary conference abstract(s). Earlier source-review dates and fictional scenes remain unchanged. October 25: reviewed the public redacted October 2 FDA classification letter and October 8 Lilly supplemental brief filed in appeal 26-1301. These establish the dated agency decision and party position, not a later appellate outcome. FDA’s unapproved-GLP-1 notice was rechecked. Historical chapters were not re-reviewed. October 28: targeted review of Lilly’s TRANSCEND-T2D-2 release, including its efficacy-estimand footnote and safety disclosures. Earlier sources were not re-reviewed; no new approval inferred. November 7: targeted review of the indexed primary ACR abstract text. Direct page retrieval returned an access error; linked figures and safety tables were not available for review. Review date is distinct from the future scheduled presentation. Earlier sources and fictional scenes were not re-reviewed.
Journal update record
2026-10-11 · Published the documented development journey in six chapters, separating fictional scenes from laboratory, animal and human evidence.
2026-10-15 · Added the October 14 research letter to the current-evidence chapter, with its observational limitations prominently displayed. Historical review dates and fictional scenes remain unchanged.
2026-10-16 · Added the October 15 UK counterfeit-pen warning. Enriched the existing September TRIUMPH-2 entry from its primary-publication abstract, distinguishing analysis methods and preserving reported deaths with investigator causality assessments. No fictional scene changed.
2026-10-23 · Added ASN animal-kidney research and a separate Lilly post hoc human biomarker analysis, with species, trial identifiers and major limitations explicit.
2026-10-25 · Added the October 2 FDA drug-versus-biologic classification decision and Lilly’s October 8 legal response and stated filing plan from original court-filed documents. Distinguished classification from safety/efficacy rejection, application submission and approval. Historical chapters and fiction are unchanged.
2026-10-28 · Added sponsor-reported TRANSCEND-T2D-2 results versus injectable Ozempic, preserving diabetes population, trial arms, efficacy estimand, adverse-event discontinuations and incomplete serious-harm reporting. No new approval or comparison with Wegovy or tirzepatide inferred.
2026-11-07 · Added a knee-osteoarthritis congress analysis, distinguishing its efficacy estimand from earlier trial estimates and preserving incomplete safety-reporting limits. The scheduled presentation has not yet occurred.
Subject One is fictional. Separate studies, species and populations are not a single patient’s experience. How to read the story